Verve Therapeutics Inc (NASDAQ: VERV) is 38.30% higher on its value in year-to-date trading and has touched a low of $4.30 and a high of $19.34 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VERV stock was last observed hovering at around $6.57 in the last trading session, with the day’s gains setting it 1.23%.
Currently trading at $7.80, the stock is 29.59% and 32.67% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.66 million and changing 18.72% at the moment leaves the stock 33.37% off its SMA200. VERV registered -34.67% loss for a year compared to 6-month loss of 8.64%. The firm has a 50-day simple moving average (SMA 50) of $5.8516 and a 200-day simple moving average (SMA200) of $5.852575.
The stock witnessed a 53.24% gain in the last 1 month and extending the period to 3 months gives it a 38.05%, and is 48.57% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.05% over the week and 9.85% over the month.
Verve Therapeutics Inc (VERV) has around 255 employees, a market worth around $660.38M and $24.40M in sales. Profit margin for the company is -807.62%. Distance from 52-week low is 81.18% and -59.67% from its 52-week high. The company has generated returns on investments over the last 12 months (-34.60%).
with sales reaching $4.24M over the same period.The EPS is expected to grow by 22.10% this year, but quarterly earnings will post 102.87% year-over-year. Quarterly sales are estimated to shrink -17.60% in year-over-year returns.
257.0 institutions hold shares in Verve Therapeutics Inc (VERV), with institutional investors hold 103.45% of the company’s shares. The shares outstanding are 84.64M, and float is at 63.10M with Short Float at 22.53%. Institutions hold 97.97% of the Float.
The top institutional shareholder in the company is ALPHABET INC. with over 12.35 million shares valued at $60.26 million. The investor’s holdings represent 14.8546 of the VERV Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 6.62 million shares valued at $32.31 million to account for 7.9632 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 5.26 million shares representing 6.3314 and valued at over $25.69 million, while T. ROWE PRICE INVESTMENT MANAGEMENT, INC. holds 5.4476 of the shares totaling 4.53 million with a market value of $22.1 million.
Verve Therapeutics Inc (VERV) Insider Activity
The most recent transaction is an insider sale by Dorval Allison, the company’s Chief Financial Officer. SEC filings show that Dorval Allison sold 555 shares of the company’s common stock on Dec 02 ’24 at a price of $5.64 per share for a total of $3130.0. Following the sale, the insider now owns 5380.0 shares.
Verve Therapeutics Inc disclosed in a document filed with the SEC on May 14 ’24 that Ashe Andrew D. bought a total of 76,000 shares of the company’s common stock. The trade occurred on May 14 ’24 and was made at $6.26 per share for $0.48 million. Following the transaction, the insider now directly holds 0.34 million shares of the VERV stock.
Still, SEC filings show that on Apr 02 ’24, Nickerson Joan (Chief Administrative Officer) disposed off 1,514 shares at an average price of $8.24 for $12475.0. The insider now directly holds 8,659 shares of Verve Therapeutics Inc (VERV).
